{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:46:51Z","timestamp":1791895611460,"version":"4.3.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.jaad.2022.12.015","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T02:38:13Z","timestamp":1671071893000},"page":"824-830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Isotretinoin and the risk of inflammatory bowel disease and irritable bowel syndrome: A large-scale global study"],"prefix":"10.1016","volume":"88","author":[{"given":"Khalaf","family":"Kridin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2022.12.015_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4088\/JCP.10r05993","article-title":"Retinoic acid and affective disorders: the evidence for an association","volume":"73","author":"Bremner","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.jaad.2022.12.015_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4161\/derm.1.3.9364","article-title":"The use of isotretinoin in acne","volume":"1","author":"Layton","year":"2009","journal-title":"Dermatoendocrinol"},{"issue":"11","key":"10.1016\/j.jaad.2022.12.015_bib3","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.3390\/ijerph19116463","article-title":"Adverse events in isotretinoin therapy: a single-arm meta-analysis","volume":"19","author":"Kapa\u0142a","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"14","key":"10.1016\/j.jaad.2022.12.015_bib4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJM198510033131401","article-title":"Retinoic acid embryopathy","volume":"313","author":"Lammer","year":"1985","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jaad.2022.12.015_bib5","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1345\/aph.10368","article-title":"Isotretinoin-induced inflammatory bowel disease in an adolescent","volume":"35","author":"Reniers","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.jaad.2022.12.015_bib6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/gut.2008.170530","article-title":"Isotretinoin and intestinal inflammation: what gastroenterologists need to know","volume":"58","author":"Shale","year":"2009","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.jaad.2022.12.015_bib7","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/j.1572-0241.2006.00632.x","article-title":"Possible association between isotretinoin and inflammatory bowel disease","volume":"101","author":"Reddy","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jaad.2022.12.015_bib8","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/ajg.2014.8","article-title":"Isotretinoin and risk of inflammatory bowel disease: a French nationwide study","volume":"109","author":"Racine","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jaad.2022.12.015_bib9","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1001\/jamadermatol.2013.1344","article-title":"Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data","volume":"149","author":"Etminan","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2022.12.015_bib10","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1038\/ajg.2009.417","article-title":"Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study","volume":"104","author":"Bernstein","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jaad.2022.12.015_bib11","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/jid.2012.387","article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study","volume":"133","author":"Alhusayen","year":"2013","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2022.12.015_bib12","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/jamadermatol.2014.1540","article-title":"Isotretinoin exposure and risk of inflammatory bowel disease","volume":"150","author":"Rashtak","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2022.12.015_bib13","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1038\/ajg.2010.124","article-title":"Isotretinoin use and the risk of inflammatory bowel disease: a case-control study","volume":"105","author":"Crockett","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jaad.2022.12.015_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaad.2020.07.042","article-title":"Risk of new-onset inflammatory bowel disease among patients with acne vulgaris exposed to isotretinoin","volume":"84","author":"Wright","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2022.12.015_bib15","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A comparison of 12 algorithms for matching on the propensity score","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"12","key":"10.1016\/j.jaad.2022.12.015_bib16","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/ajg.2010.303","article-title":"Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease","volume":"105","author":"Margolis","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaad.2022.12.015_bib17","article-title":"Case-control studies: advantages and disadvantages","volume":"348","author":"Sedgwick","year":"2014","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jaad.2022.12.015_bib18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00403-021-02317-9","article-title":"Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiation","volume":"315","author":"Kridin","year":"2023","journal-title":"Arch Dermatol Res"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222033047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222033047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T23:08:43Z","timestamp":1759273723000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222033047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0190962222033047"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.12.015","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isotretinoin and the risk of inflammatory bowel disease and irritable bowel syndrome: A large-scale global study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}